AVDL
Avadel Pharmaceuticals
NASDAQ · Pharmaceuticals
$21.69
+0.09 (+0.42%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 173.87M | 88.54M | 349.90M | 342.21M | 329.87M |
| Net Income | -50,209,770 | -23,012,065 | 87.87M | 102.70M | 88.69M |
| EPS | — | — | — | — | — |
| Profit Margin | -28.9% | -27.4% | 25.1% | 30.0% | 26.9% |
| Rev Growth | +96.4% | +96.4% | +15.0% | -4.7% | +6.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 342.74M | 342.74M | 865.57M | 835.52M | 800.53M |
| Total Equity | 718.09M | 718.09M | 1.40B | 1.38B | 1.39B |
| D/E Ratio | 0.48 | 0.48 | 0.62 | 0.61 | 0.58 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -36,564,216 | -17,689,059 | 157.77M | 141.15M | 147.31M |
| Free Cash Flow | — | — | 68.00M | 87.98M | 76.45M |